Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8601 in CABG Patients With Impaired Systolic Function
NCT03370887Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Primary completion
- Jun 2021
- Modality
- mRNA Therapeutics
- Countries
- 5
01
Overview
A Phase 2 trial of AZD-8601 in heart failure (HF), sponsored by AstraZeneca. Started Feb 2018; status: completed.
02
Drugs
AZD-8601
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03370887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370887.